In men with hormone-sensitive prostate cancer, enzalutamide and apalutamide improve overall survival compared with androgen deprivation therapy alone. Also, radiotherapy of the primary tumour is beneficial in patients with low tumour burden. In the non-metastatic castration-resistant setting, a positive trial for darolutamide was reported. In the metastatic castration-resistant setting, the role of cabazitaxel in treatment sequencing was clarified.

中文翻译：

---

各种晚期前列腺癌的治疗进展。

在激素敏感性前列腺癌的男性中，与单独的雄激素剥夺疗法相比，enzalutamide和apalutamide改善了总体生存率。同样，对肿瘤负荷低的患者，原发性肿瘤的放射治疗是有益的。据报道，在非转移性去势抵抗环境中，对他洛鲁胺有阳性试验报道。在抵抗转移性去势的情况下，卡巴他赛在治疗序列中的作用被阐明。